* denotes a publication that resulted from CTD2 intra-Network collaborations
The comprehensive characterization of a large number of cancer genomes will eventually lead to a compendium of genetic alterations in specific cancers.
Researchers describe emerging approaches that aim to determine which altered genes are actually contributing to cancer, as well as their potential as therapeutic targets.
Investigators screemed a library of kinases that lead to activation of the MAPK pathway and identified PAK1.
Glioblastoma is both the most common and lethal primary malignant brain tumor.
The fusion of empirical science with large-scale computing platforms has allowed rapid advances in our ability to model physiological and pathophysiological processes in silico.
A comprehensive understanding of the molecular vulnerabilities of every type of cancer will provide a powerful roadmap to guide therapeutic approaches.
The authors introduce a small molecule to induce apoptosis selectively in cancer cells.